Peter Westervelt

62.1k total citations
195 papers, 5.7k citations indexed

About

Peter Westervelt is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Peter Westervelt has authored 195 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Hematology, 47 papers in Molecular Biology and 42 papers in Oncology. Recurrent topics in Peter Westervelt's work include Acute Myeloid Leukemia Research (95 papers), Hematopoietic Stem Cell Transplantation (85 papers) and Acute Lymphoblastic Leukemia research (39 papers). Peter Westervelt is often cited by papers focused on Acute Myeloid Leukemia Research (95 papers), Hematopoietic Stem Cell Transplantation (85 papers) and Acute Lymphoblastic Leukemia research (39 papers). Peter Westervelt collaborates with scholars based in United States, Canada and United Kingdom. Peter Westervelt's co-authors include John F. DiPersio, Ravi Vij, Lee Ratner, Geoffrey L. Uy, Timothy J. Ley, Keith Stockerl‐Goldstein, Howard E. Gendelman, Camille N. Abboud, Michael P. Rettig and Amanda F. Cashen and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Peter Westervelt

190 papers receiving 5.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peter Westervelt 3.2k 1.8k 1.4k 1.4k 726 195 5.7k
Giuseppe Visani 4.0k 1.2× 2.2k 1.2× 930 0.7× 1.4k 1.1× 411 0.6× 285 6.6k
Elaine M. Sloand 2.5k 0.8× 991 0.5× 1.4k 1.0× 535 0.4× 453 0.6× 117 4.8k
Amrita Krishnan 2.9k 0.9× 2.2k 1.2× 721 0.5× 2.8k 2.1× 274 0.4× 198 5.6k
Dale L. Bixby 1.6k 0.5× 1.1k 0.6× 432 0.3× 756 0.6× 365 0.5× 135 3.2k
François Dreyfus 4.0k 1.2× 3.0k 1.7× 721 0.5× 1.0k 0.8× 97 0.1× 126 6.2k
Renato Zambello 1.6k 0.5× 1.6k 0.9× 3.9k 2.9× 2.0k 1.5× 378 0.5× 288 8.0k
Marinus H. J. van Oers 1.7k 0.5× 1.9k 1.0× 3.2k 2.3× 2.8k 2.1× 233 0.3× 175 9.0k
Livio Trentin 1.0k 0.3× 1.8k 1.0× 3.6k 2.6× 1.9k 1.4× 366 0.5× 332 8.6k
Eckhart Weidmann 770 0.2× 1.4k 0.8× 1.3k 1.0× 2.0k 1.4× 214 0.3× 111 5.0k
Georg Heß 758 0.2× 1.1k 0.6× 1.2k 0.9× 2.2k 1.6× 251 0.3× 192 6.6k

Countries citing papers authored by Peter Westervelt

Since Specialization
Citations

This map shows the geographic impact of Peter Westervelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Westervelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Westervelt more than expected).

Fields of papers citing papers by Peter Westervelt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Westervelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Westervelt. The network helps show where Peter Westervelt may publish in the future.

Co-authorship network of co-authors of Peter Westervelt

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Westervelt. A scholar is included among the top collaborators of Peter Westervelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Westervelt. Peter Westervelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saber, Wael, Aasthaa Bansal, Bart L. Scott, et al.. (2024). Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. JCO Oncology Practice. 20(4). 572–580. 6 indexed citations
2.
Ghobadi, Armin, Michael P. Rettig, Amanda F. Cashen, et al.. (2023). Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Advances. 8(3). 513–522. 6 indexed citations
3.
Abel, Haley, Karolyn A. Oetjen, Christopher A. Miller, et al.. (2023). Genomic landscape of TP53-mutated myeloid malignancies. Blood Advances. 7(16). 4586–4598. 15 indexed citations
4.
Choi, Jaebok, Matthew Cooper, Mark A. Fiala, et al.. (2023). Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 29(11). 699.e1–699.e9. 2 indexed citations
5.
6.
7.
Pusic, Iskra, Tanner M. Johanns, Stefanie Sarantopoulos, et al.. (2021). Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. Blood. 138(Supplement 1). 3904–3904. 1 indexed citations
8.
9.
Ali, Alaa M., Feng Gao, Geoffrey L. Uy, et al.. (2017). Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen. Cancer Medicine. 6(12). 2814–2821. 21 indexed citations
10.
Lee, Yi-Shan, Jingxia Liu, Ravi Vij, et al.. (2017). Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 23(12). 2199–2204. 7 indexed citations
11.
Cashen, Amanda F., John F. DiPersio, Meagan A. Jacoby, et al.. (2017). A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS. Blood. 130. 5067–5067. 3 indexed citations
12.
Jacoby, Meagan A., Eric J. Duncavage, Gue Su Chang, et al.. (2017). Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant. Blood. 130. 4232. 1 indexed citations
13.
Rashidi, Armin, John F. DiPersio, Peter Westervelt, et al.. (2016). Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. Biology of Blood and Marrow Transplantation. 22(6). 1137–1141. 8 indexed citations
14.
Rashidi, Armin, Michael Slade, John F. DiPersio, et al.. (2016). Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplantation. 51(12). 1561–1564. 25 indexed citations
15.
Ghobadi, Armin, Mark A. Fiala, Giridharan Ramsingh, et al.. (2015). CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. Blood. 126(23). 3098–3098. 1 indexed citations
16.
Uy, Geoffrey L., Michael P. Rettig, Ibraheem Motabi, et al.. (2012). A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 119(17). 3917–3924. 310 indexed citations
17.
Fehniger, Todd A., Geoffrey L. Uy, Kathryn Trinkaus, et al.. (2010). A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 117(6). 1828–1833. 82 indexed citations
18.
Devine, Steven M., Ravi Vij, Michael P. Rettig, et al.. (2008). Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 112(4). 990–998. 234 indexed citations
19.
Černý, Jan, et al.. (2006). Low incidence of JAK2 and FLT3 mutations in patients with chronic myelomonocytic leukemia (CMML). Cancer Research. 66. 305–305. 1 indexed citations
20.
Ratner, Lee, et al.. (1991). Formation of Noninfectious HIV-1 Virus Particles Lacking a Full-Length Envelope Protein. AIDS Research and Human Retroviruses. 7(3). 287–294. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Visani Breakdown of academic impact, for papers by Elaine M. Sloand Breakdown of academic impact, for papers by Amrita Krishnan Breakdown of academic impact, for papers by Dale L. Bixby Breakdown of academic impact, for papers by François Dreyfus Breakdown of academic impact, for papers by Renato Zambello Breakdown of academic impact, for papers by Marinus H. J. van Oers Breakdown of academic impact, for papers by Livio Trentin Breakdown of academic impact, for papers by Eckhart Weidmann Breakdown of academic impact, for papers by Georg Heß
Rankless by CCL
2026